ECG-AI to Assist with the Classification of Low Ejection Fraction and Heart Failure with Preserved Ejection Fraction
Abstract Body (Do not enter title and authors here): Background There are delays on identification of people with low left ventricular ejection fraction (LVEF) and Heart Failure with preserved EF (HFpEF). There is a need for low cost and accessible tools to identify individuals who can benefit from more comprehensive exams such as echocardiogram (ECHO). Research Goal To develop electrocardiographic artificial intelligence (ECG-AI) models that can classify low EF and HFpEF. Methods We developed an ECG-AI model using convolutional neural networks to classify 12-lead ECG’s into four categories: rEF( LVEF<40), mEF (40≤LVEF<50), HFpEF (clinical HF diagnosis with EF≥50) and controls with no HF diagnosis within 5-years of the index ECG. For rEF, mEF, and HFpEF categories, ECHO were used to determine LVEF. Patients with clinical HF diagnosis without ECHO data were excluded. In patients with ECHO, only available ECGs within 30-days of the ECHO study was utilized. The ECG-AI models were trained on ~80%, validated on ~10%, and tested on the remaining 10% hold out data from Wake Forest Baptist Health (WFBH) ECG repository and externally validated using data from the University of Tennessee Health Science Center (UTHSC). Results The ECG-AI model was developed using 1,078,198 digital ECGs, 114,068 ECHO derived LVEF values, and EHR data from 165,243 patients (73% White, 19% Black, 52% female, with a mean age (SD) of 58(15) years). There were 32,962, 40,997, 11,037, and 993,202 ECGs from 8,555 rEF, 13,116 mEF, 3,704 HFpEF, and 139,868 control patients, respectively. The ECG-AI achieved a hold-out AUC of 0.76 (0.74-0.77) in classifying ECGs as HFpEF or not (Table 1). The UTHSC external validation cohort included 273 rEF, 167 mEF, 459 HFpEF, and 35,254 control patients, with 35% White, 62% Black, 60% female, mean age of 51(18) years. Our model identified HFpEF patients with an AUC of 0.75 (0.73-0.76) in the UTHSC cohort. Conclusion ECG data alone result in moderate, moderately high, and very high accuracies in classifying HFpEF, mEF, and rEF, respectively. This could guide future models with incorporation of simple patient demographics and comorbidities to improve accuracy. Such ECG-AI models can assist with identifying who may benefit from further clinical evaluation and imaging studies.
Karabayir, Ibrahim
( Wake Forest School of Medicine
, Winston Salem
, North Carolina
, United States
)
Kitzman, Dalane
( Wake Forest School of Medicine
, Winston Salem
, North Carolina
, United States
)
Herrington, David
( Wake Forest School of Medicine
, Winston Salem
, North Carolina
, United States
)
Akbilgic, Oguz
( Wake Forest School of Medicine
, Winston Salem
, North Carolina
, United States
)
Davis, Robert
( University of Tennessee Health Science Center
, Memphis
, Tennessee
, United States
)
Tootooni, M. Samie
( Loyola University Chicago
, Maywood
, Illinois
, United States
)
Chinthala, Lokesh
( University of Tennessee Health Science Center
, Memphis
, Tennessee
, United States
)
Soliman, Elsayed
( Wake Forest School of Medicine
, Winston Salem
, North Carolina
, United States
)
Jefferies, John
( University of Memphis
, Memphis
, Tennessee
, United States
)
Baykaner, Tina
( Stanford University
, Palo Alto
, California
, United States
)
Shah, Sanjiv
( NORTHWESTERN UNIVERSITY
, Chicago
, Illinois
, United States
)
Bertoni, Alain
( Wake Forest School of Medicine
, Winston Salem
, North Carolina
, United States
)
Author Disclosures:
Ibrahim Karabayir:DO NOT have relevant financial relationships
| Dalane Kitzman:DO have relevant financial relationships
;
Royalties/Patent Beneficiary:Pfizer:Active (exists now)
; Consultant:Rivus:Active (exists now)
; Research Funding (PI or named investigator):Rivus:Active (exists now)
; Consultant:novonordisk:Active (exists now)
; Research Funding (PI or named investigator):novonordisk:Active (exists now)
; Research Funding (PI or named investigator):pfizer:Active (exists now)
| David Herrington:DO have relevant financial relationships
;
Researcher:esperion:Past (completed)
; Researcher:amgen:Active (exists now)
; Researcher:astra zenica:Active (exists now)
| Oguz Akbilgic:DO have relevant financial relationships
;
Consultant:Daxor:Active (exists now)
; Advisor:Anumana:Active (exists now)
| Robert Davis:DO have relevant financial relationships
;
Ownership Interest:9and1ai, LLC:Active (exists now)
| M. Samie Tootooni:DO NOT have relevant financial relationships
| Lokesh Chinthala:No Answer
| Elsayed Soliman:DO NOT have relevant financial relationships
| John Jefferies:DO NOT have relevant financial relationships
| Tina Baykaner:DO NOT have relevant financial relationships
| Sanjiv Shah:DO have relevant financial relationships
;
Consultant:Bayer:Active (exists now)
; Consultant:Merck:Active (exists now)
; Consultant:Axon Therapies:Active (exists now)
; Consultant:Corvia :Active (exists now)
; Consultant:Boehringer-Ingelheim:Active (exists now)
; Consultant:Bristol-Myers Squibb:Active (exists now)
; Consultant:Ionis:Active (exists now)
; Consultant:Novartis:Active (exists now)
; Consultant:Tenax:Active (exists now)
; Consultant:Intellia:Active (exists now)
; Consultant:Rivus:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
; Consultant:Lilly:Active (exists now)
; Consultant:Pfizer:Active (exists now)
; Consultant:AstraZeneca:Active (exists now)
| Alain Bertoni:DO NOT have relevant financial relationships